Certara, Inc. (NASDAQ:CERT) Shares Acquired by Barclays PLC

Barclays PLC raised its holdings in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 198.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 70,525 shares of the company's stock after buying an additional 46,880 shares during the period. Barclays PLC's holdings in Certara were worth $825,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Jane Street Group LLC boosted its holdings in Certara by 2.6% during the 3rd quarter. Jane Street Group LLC now owns 147,393 shares of the company's stock valued at $1,726,000 after acquiring an additional 3,732 shares during the period. State Street Corp boosted its stake in shares of Certara by 3.4% during the third quarter. State Street Corp now owns 3,679,699 shares of the company's stock valued at $43,089,000 after purchasing an additional 122,411 shares during the period. Petrus Trust Company LTA bought a new position in shares of Certara in the third quarter worth about $994,000. Paloma Partners Management Co purchased a new position in Certara in the 3rd quarter worth about $413,000. Finally, 272 Capital LP bought a new stake in Certara during the 3rd quarter valued at about $177,000. Institutional investors own 73.96% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Robert W. Baird dropped their target price on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. UBS Group upgraded Certara from a "neutral" rating to a "buy" rating and set a $16.00 price objective on the stock in a report on Friday, September 27th. Finally, Barclays dropped their price target on Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Certara has a consensus rating of "Hold" and an average price target of $15.92.

Certara Stock Down 0.5 %

Shares of NASDAQ:CERT traded down $0.06 during trading on Thursday, reaching $11.90. The stock had a trading volume of 664,372 shares, compared to its average volume of 946,876. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.92 billion, a P/E ratio of -59.55, a PEG ratio of 4.55 and a beta of 1.52. The firm's 50-day simple moving average is $10.88 and its 200 day simple moving average is $11.95. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The business's quarterly revenue was up 10.7% on a year-over-year basis. During the same quarter last year, the firm earned $0.06 EPS. As a group, research analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.